TQ80 Stock Overview A biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Theratechnologies Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Theratechnologies Historical stock prices Current Share Price CA$1.37 52 Week High CA$2.04 52 Week Low CA$0.96 Beta 1.5 1 Month Change -27.13% 3 Month Change 28.04% 1 Year Change 0% 3 Year Change -87.50% 5 Year Change -86.41% Change since IPO -88.58%
Recent News & Updates
Theratechnologies Provides Update on EGRIFTA SV® Supply Jan 10
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA Dec 11
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1B, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer Dec 10 Theratechnologies Inc. Announces Resume Production of EGRIFTA SV Dec 04
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review Nov 26
Theratechnologies Presents Data on Tesamorelin's Role in Reducing Cardiovascular Risk in People with Hiv At Idweek 2024 Oct 18 See more updates
Theratechnologies Provides Update on EGRIFTA SV® Supply Jan 10
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA Dec 11
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1B, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer Dec 10 Theratechnologies Inc. Announces Resume Production of EGRIFTA SV Dec 04
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review Nov 26
Theratechnologies Presents Data on Tesamorelin's Role in Reducing Cardiovascular Risk in People with Hiv At Idweek 2024 Oct 18 Theratechnologies Inc. Revises Earnings Guidance for the Fiscal Year 2024 Oct 11
Third quarter 2024 earnings released: EPS: US$0.06 (vs US$0.031 loss in 3Q 2023) Oct 10
New major risk - Share price stability Sep 25
Forecast breakeven date pushed back to 2025 Sep 18
Forecast to breakeven in 2025 Jul 12
Second quarter 2024 earnings released: EPS: US$0.02 (vs US$0.41 loss in 2Q 2023) Jul 11
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024 Jul 10
Insufficient new directors Jul 01
Theratechnologies Inc. to Report Q2, 2024 Results on Jul 10, 2024 Jun 27
Forecast to breakeven in 2024 Jun 02
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors May 11
First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.43 loss in 1Q 2023) Apr 12 Theratechnologies Inc. Provides Earnings Guidance for the Fiscal Year 2024
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee Apr 06
Theratechnologies Inc. to Report Q1, 2024 Results on Apr 10, 2024 Apr 04 Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc., Annual General Meeting, May 09, 2024 Mar 09 Theratechnologies Inc. Announces Board Changes
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024 Feb 22
Full year 2023 earnings released: US$0.91 loss per share (vs US$1.98 loss in FY 2022) Feb 22
Theratechnologies Inc. Announces Publication in Frontiers in Immunology That Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action Feb 22
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer Feb 16
Theratechnologies Inc. to Report Q4, 2023 Results on Feb 21, 2024 Feb 07 Theratechnologies Inc. Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Theratechnologies Inc. Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose Dec 13
Soleus Capital Management Engages in Discussions with Theratechnologies Nov 30
Soleus Capital Management Engages in Discussions with Theratechnologies Nov 29 Theratechnologies Inc. announced that it has received $12.5 million in funding from Investissement Québec Nov 01
Insufficient new directors Nov 01 Theratechnologies Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million. Oct 28
Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec Oct 26
Theratechnologies Inc. Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV Oct 20 Theratechnologies Inc. Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer Oct 13
Theratechnologies Inc. Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA Oct 06
Third quarter 2023 earnings released: US$0.03 loss per share (vs US$0.32 loss in 3Q 2022) Sep 27
Theratechnologies Submits Tesamorelin F8 Formulation Sbla for Fda Review Sep 26
Theratechnologies Inc. to Report Q3, 2023 Results on Sep 26, 2023 Sep 19
Theratechnologies Inc. Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide Aug 31
New major risk - Revenue and earnings growth Aug 11
New major risk - Share price stability Aug 03 Theratechnologies Completes 1-For-4 Reverse Stock Split to Regain Compliance with Nasdaq Listing Requirements Aug 01
Theratechnologies Inc. Announces Resignation of Gary Littlejohn as Board of Directors and Member of Its Audit Committee
Theratechnologies Inc. Revises Revenue Guidance for the Fiscal Year of 2023 Jul 13
New major risk - Revenue and earnings growth Jul 13
Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.24 loss in 2Q 2022) Jul 13
New minor risk - Profitability Jul 03
Forecast to breakeven in 2025 Jul 03
Theratechnologies Inc. to Report Q2, 2023 Results on Jul 12, 2023 Jun 30
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for Its Lead PDC Candidate Sudocetaxel Zendusortide Jun 03
Theratechnologies Inc.'s Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison May 05
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.095 loss in 1Q 2022) Apr 13
Full year 2022 earnings released: US$0.50 loss per share (vs US$0.34 loss in FY 2021) Mar 01
Theratechnologies Inc. Announces Path to Resume TH1902 Clinical Development Feb 17
Theratechnologies Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 15 Shareholder Returns TQ80 DE Biotechs DE Market 7D -4.9% 2.3% 0.5% 1Y 0% -2.6% 15.3%
See full shareholder returns
Return vs Market: TQ80 underperformed the German Market which returned 13.7% over the past year.
Price Volatility Is TQ80's price volatile compared to industry and market? TQ80 volatility TQ80 Average Weekly Movement 13.2% Biotechs Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: TQ80's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TQ80's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
Show more Theratechnologies Inc. Fundamentals Summary How do Theratechnologies's earnings and revenue compare to its market cap? TQ80 fundamental statistics Market cap €67.45m Earnings (TTM ) -€3.04m Revenue (TTM ) €81.17m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TQ80 income statement (TTM ) Revenue US$84.32m Cost of Revenue US$19.42m Gross Profit US$64.90m Other Expenses US$68.06m Earnings -US$3.16m
Last Reported Earnings
Aug 31, 2024
Earnings per share (EPS) -0.069 Gross Margin 76.97% Net Profit Margin -3.75% Debt/Equity Ratio -290.4%
How did TQ80 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/06 09:15 End of Day Share Price 2025/02/06 00:00 Earnings 2024/08/31 Annual Earnings 2023/11/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Theratechnologies Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Zhang BMO Capital Markets U.S. (Historical) Douglas Loe Byron Capital Markets Dewey Steadman Canaccord Genuity
Show 14 more analysts 
